Literature DB >> 21496466

MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model.

Jeong-Im Sin1.   

Abstract

The function of MyD88 signals for induction of adaptive immunity is still controversial. Here we investigate using a human papillomavirus (HPV) 16 E7 DNA vaccine on MyD88 knock out mouse model whether MyD88 signals are required for induction of Ag-specific antibody and cellular responses, as well as antitumor resistance. When injected intramuscularly with E7 DNA vaccines, MyD88 deficient mice displayed antitumor protective responses to tumor cell challenges while having far lower responses than wild type mice. A similar finding was observed in antitumor therapeutic models by intramuscular-electroporation of E7 DNA vaccines. E7 DNA vaccines induced Ag-specific humoral and CD8+ CTL responses in MyD88 deficient mice. However, the levels were much less than those of wild type mice. These data suggest that the immune stimulatory sequence of E7 DNA vaccines and its signaling through MyD88 are not absolutely essential for induction of adaptive immune responses. However, MyD88 deficient mice co-delivered with MyD88 cDNA plus E7 DNA vaccines showed a recovery of Ag-specific IgG and CTL responses, and antitumor immunity to the levels of wild type mice, highlighting the importance of MyD88 signals for augmenting an adaptive immune response. Thus, these data clearly show that MyD88 signals are required only for more efficient induction of Ag-specific humoral and antitumor CD8+ CTL responses in this model.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21496466     DOI: 10.1016/j.vaccine.2011.03.098

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.

Authors:  Kyusun Torque Han; Jeong-Im Sin
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

2.  Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model.

Authors:  Chung Truong Nguyen; Seol Hee Hong; Thuan Trong Ung; Vivek Verma; Soo Young Kim; Joon Haeng Rhee; Shee Eun Lee
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

3.  DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.

Authors:  Haifa H Jabara; Douglas R McDonald; Erin Janssen; Michel J Massaad; Narayanaswamy Ramesh; Arturo Borzutzky; Ingrid Rauter; Halli Benson; Lynda Schneider; Sachin Baxi; Mike Recher; Luigi D Notarangelo; Rima Wakim; Ghassan Dbaibo; Majed Dasouki; Waleed Al-Herz; Isil Barlan; Safa Baris; Necil Kutukculer; Hans D Ochs; Alessandro Plebani; Maria Kanariou; Gerard Lefranc; Ismail Reisli; Katherine A Fitzgerald; Douglas Golenbock; John Manis; Sevgi Keles; Reuben Ceja; Talal A Chatila; Raif S Geha
Journal:  Nat Immunol       Date:  2012-05-13       Impact factor: 25.606

4.  Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.

Authors:  Devon J Shedlock; Colleen Tingey; Lavanya Mahadevan; Natalie Hutnick; Emma L Reuschel; Sagar Kudchodkar; Seleeke Flingai; Jenny Yan; Joseph J Kim; Kenneth E Ugen; David B Weiner; Kar Muthumani
Journal:  Vaccines (Basel)       Date:  2014-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.